|
Canada-BC-MISSION Azienda Directories
|
Azienda News:
- Advances in Lung Cancer Research - NCI - National Cancer Institute
This page highlights some of the latest research in non-small cell lung cancer (NSCLC), the most common form of lung cancer Read on for clinical advances that may soon translate into improved care, NCI-supported programs that are fueling progress, and research findings from recent studies The following are some of our latest news articles
- Lung Cancer Research Articles - NCI
Find research articles on lung cancer, which may include news stories, clinical trials, blog posts, See Advances in Lung Cancer Research for an overview of recent findings and progress, (Xalkori) as an initial treatment for people with ALK-positive advanced non-small cell lung cancer, according to new clinical trial results Treatment
- News Events - NCI - National Cancer Institute
NIH researchers discover tissue biomarker that may indicate higher risk of aggressive breast cancer development and death May 14, 2025; A series of tissue changes may be associated with an increased risk of developing aggressive breast cancer among women with benign breast disease, and poorer rates of survival among women with invasive breast
- Cancer Currents: An NCI Cancer Research Blog - NCI
The Cancer Currents blog provides news and research updates from the National Cancer Institute to treat people with pancreatic or non-small cell lung cancer whose tumors have a rare genetic alteration called an NRG1 fusion doctors aren’t using the recommended initial treatments for their patients with hormone-sensitive metastatic
- Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI
In November 2023, the Food and Drug Administration (FDA) approved repotrectinib (Augtyro) for the treatment of some advanced lung cancers that have a genetic change called a ROS1 gene fusion Now, the complete results of the clinical trial that led to the approval of repotrectinib have been published In the study, nearly 80% of the participants with non-small cell lung cancer (NSCLC) who had
- Osimertinib Improves Survival in Lung Cancer - NCI
The findings “herald a new era of targeted therapy in early-stage [lung cancer],” said the trial’s lead investigator, Roy Herbst, M D , of the Yale Cancer Center, who presented the data on June 4 at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO)
- Lung Cancer Risk Variants Characterized - NCI
Multiple genetic loci are associated with lung cancer risk, but the underlying genetic mechanisms remain poorly understood Dr Jiyeon Choi from the Laboratory of Translational Genomics and her colleagues analyzed normal lung cells from ever- and never-smokers using single-cell multiomics The data highlighted cell-type-specific gene regulation underlying lung cancer susceptibility
- FDA Approves Alectinib for ALK-Positive Lung Cancer
Before receiving alectinib—either after surgery or for cancer that has metastasized—people with lung cancer must have the ALK status of their tumors confirmed by an FDA-approved test The number of drugs that target specific genetic changes in lung cancer highlights the importance of ensuring that oncologists test tumors in all of their patients, including those with earlier stage disease
- Imfinzi Improves Survival in Small Cell Lung Cancer - NCI
The findings are “definitely practice changing,” said Anish Thomas, M D , of NCI’s Center for Cancer Research, who studies small cell lung cancer but wasn’t involved in the new trial “This is really encouraging for patients as well as people who are working on this cancer,” Dr Thomas said
- Metastatic Cancer Research - NCI - National Cancer Institute
Find research articles about metastatic cancer, which may include news stories, clinical trials, blog The approval also covers adults with non-small cell lung cancer harboring a ROS1 gene fusion NCI’s Dr Rosandra Kaplan discusses important trends in metastatic cancer research and new ideas for treating and preventing metastatic
|
|